Is It a Simple Stress Fracture or Bisphosphonate-related Atypical Fracture?
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
A number of reports regarding atypical fractures of the femur have raised questions concerning the possible correlation between long-term bisphosphonate treatment and the occurrence of insufficiency fractures in the proximal femur. However, clinically, it is often confused whether is it a fatigue fracture because of implant induced stress concentration or a bisphosphonate-related atypical fracture, especially in a patient with a subtrochanteric fracture who receive bisphosphonate therapy after open reduction and internal fixation, such as dynamic hip screw (DHS) fixation for previous ipsilateral femoral neck or intertrochanteric fracture. The authors experienced a case of a progressive femoral insufficiency fracture in a woman who had been on Fosamax (Alendronic acid with Vitamin D; Merck & Co. Inc, NJ,USA) therapy for four years after ipsilateral femoral neck fracture treated with a two hole DHS system. Despite a high suspicion of an insufficiency femoral subtrochanteric fracture by bone scan, the occult fracture progressed to a displaced femoral subtrochanteric fracture one year after. The fracture site was fixed with a 6 hole DHS plate, and six months after reoperation the patient had no symptoms and the fracture site had united without any complication.
Abstract
A number of reports regarding atypical fractures of the femur have raised questions concerning the possible correlation between long-term bisphosphonate treatment and the occurrence of insufficiency fractures in the proximal femur. However, clinically, it is often confused whether is it a fatigue fracture because of implant induced stress concentration or a bisphosphonate-related atypical fracture, especially in a patient with a subtrochanteric fracture who receive bisphosphonate therapy after open reduction and internal fixation, such as dynamic hip screw (DHS) fixation for previous ipsilateral femoral neck or intertrochanteric fracture. The authors experienced a case of a progressive femoral insufficiency fracture in a woman who had been on Fosamax (Alendronic acid with Vitamin D; Merck & Co. Inc, NJ,USA) therapy for four years after ipsilateral femoral neck fracture treated with a two hole DHS system. Despite a high suspicion of an insufficiency femoral subtrochanteric fracture by bone scan, the occult fracture progressed to a displaced femoral subtrochanteric fracture one year after. The fracture site was fixed with a 6 hole DHS plate, and six months after reoperation the patient had no symptoms and the fracture site had united without any complication.
참고문헌 (8)
- Odvina CV, "Severely suppressed bone turnover: a potential complication of alendronate therapy", J Clin Endocrinol Metab, 90, pp.1294~1301 (2005)
- Goh SK, "Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution", J Bone Joint Surg Br, 89, pp.349~353 (2007)
- Kwek EB, "An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy?", Injury, 39, pp.224~231 (2008)
- Capeci CM, "Bilateral low-energy simultaneous or sequential femoral fractures in patients on long-term alendro-nate therapy", J Bone Joint Surg Am, 91, pp.2556~2561 (2009)
- Ha YC, "Is surgery necessary for femoral insufficiency fractures after long-term bisphosphonate therapy?", Clin Orthop Relat Res, 468, pp.3393~3398 (2010)
- Visekruna M, "Severely suppressed bone turnover and atypical skeletal fragility", J Clin Endocrinol Metab, 93, pp.2948~2952 (2008)
- McKiernan FE, "A long femur scan field does not alter proximal femur bone mineral density measurements by dual-energy X-ray absorptiometry", J Clin Densitom, 14, pp.354~358 (2011)
- Puah KL, "Bisphosphonate-associated atypical fracture of the femur: Spontaneous healing with drug holiday and re-appearance after resumed drug therapy with bilateral simultaneous displaced fractures--a case report", Acta Orthop, 82, pp.380~382 (2011)